Catalym GmbH reported in an oral session at the European Society for Medical Oncology meeting in Paris that its first-in-class growth differentiation factor 15 inhibitor, visugromab, demonstrated preliminary signs of efficacy in a heavily pretreated group of cancer patients who were resistant or refractory to checkpoint inhibitors.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2022, including: Adaptimmune, Curelab, Novartis.
Genexine Co. Ltd.’s DNA vaccine, GX-188E, showed potential in extending overall survival in patients with advanced cervical cancer in a phase II study when given in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab).
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2022, including: Debiopharm, Elevar, Genexine, Gilead, Hutchmed, Innovent.
ESMO late breakers were released Sept. 8, and scientifically at least, a key theme of the meeting will be that cell therapies, at long last, are capable of besting solid tumors.
Shanghai Junshi Biosciences Co. Ltd. plans to raise up to ¥3.969 billion (US$570 million) by issuing no more than 70 million A shares to target subscribers on the Shanghai STAR Market.
Arsenal Biosciences Inc. closed on an oversubscribed $220 million series B financing so it could continue developing its programmable cell therapy research programs and its candidates for treating solid tumor malignancies. Arsenal’s lead program is AB-1015 for treating ovarian cancer.
For privately held Good Therapeutics Inc., founded in 2016 with a platform technology for developing context-dependent therapeutics, the plan had always been to seek a buyer for the first asset to emerge. One came along a little earlier than expected, as Roche Holding AG entered a merger agreement for Good, picking up preclinical-stage PD-1-regulated IL-2 program, in exchange for an up-front cash payment of $250 million.
Pleco Therapeutics BV has raised €17.3 million (US$17.1 million) in equity, loan and grant financing to move its lead program into a phase I trial next year. The company, based in Nijmegen, the Netherlands, is bringing a fresh perspective to bear on a longstanding therapeutic concept – that cancer can be tackled by metal chelation. Quite a number of agents have entered the clinic over the years, but none as yet has delivered any useful outcome.
Biocytogen Pharmaceuticals Co. Ltd. has raised HK$471.1 million (US$60 million) in net proceeds through an initial public offering on the Hong Kong Stock Exchange Sept. 1. It plans to use about three-quarters of the proceeds to advance clinical trials of two of its core anticancer candidates, YH-003 and YH-001. Company shares (HKEX:2315), initially offered at HK$25.22 each, closed at HK$26 on their first trading day.
RSS
